SCHEMBL1917263

SCHEMBL1917263

COc1ccc2sc(CN3CCOCC3)nc2c1N

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
ADORA2A P29274 2/20 0.39
ADORA1 P30542 1/20 0.39
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PDE4B Q07343 2/20 0.37
PDE7A Q13946 1/20 0.37
PDE3A Q14432 1/20 0.37
PDE10A Q9Y233 1/20 0.37
CXCR4 P61073 1/20 0.37
FGFR1 P11362 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1916585 0.83 KCNJ1 (0.42) HTTSMN1; SMN2ALDH1A1HSD17B10LMNA
SCHEMBL2398989 0.75 HPGD (0.47) HTTSMN1; SMN2ALDH1A1ADORA2AADORA1
SCHEMBL3051370 0.74 SMN1; SMN2 (0.46) HTTSMN1; SMN2ALDH1A1HSD17B10ADORA2A
SCHEMBL1917781 0.73 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1ADORA2AADORA1KDM4E
SCHEMBL3054743 0.68 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1HSD17B10ADORA2AADORA1
SCHEMBL4556469 0.67 KDM4E (0.42) ALDH1A1HSD17B10ADORA2AADORA1KDM4E
SCHEMBL922423 0.66 HTT (0.55) HTTSMN1; SMN2ALDH1A1HSD17B10KDM4E
SCHEMBL519845 0.66 HTT (0.70) HTTSMN1; SMN2ALDH1A1PDE4B
SCHEMBL24366831 0.66 LOXL2 (0.55) ALDH1A1
SCHEMBL30470713 0.66 LOXL2 (0.55) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2335702-A1 Product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent IPSEN PHARMA (FR) 2011-06-22 EP disclosed
US-20090253685-A1 Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFICQUES 2009-10-08 US disclosed
EP-1641453-B1 PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT IPSEN PHARMA (FR) 2009-08-19 EP disclosed
US-20090137596-A1 G-PROTEIN INHIBITOR SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-28 US disclosed
US-20090131428-A1 BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-21 US disclosed
US-20090082345-A1 BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-03-26 US disclosed
US-7495021-B2 Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-02-24 US disclosed
US-20070293487-A1 BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS SOCIET DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-12-20 US disclosed
US-20070255063-A1 BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-11-01 US disclosed
US-7279467-B2 Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-10-09 US disclosed
EP-1461326-B1 BENZOTHIAZOLE- AND BENZOXAZOLE-4,7-DIONE DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATASE INHIBITORS SOD CONSEILS RECH APPLIC (FR) 2007-08-01 EP disclosed
EP-1792905-A1 Product containing at least one phosphatase CDC25 inhibitor combined with at least one other anticancer agent Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2007-06-06 EP disclosed
US-20060281736-A1 Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2006-12-14 US disclosed
US-20060040996-A1 Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors IPSEN PHARMA S.A.S. (FR) 2006-02-23 US disclosed
EP-1461326-A1 BENZOTHIAZOLE- AND BENZOXAZOLE-4,7-DIONE DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-09-29 EP disclosed
WO-2003055868-A1 BENZOTHIAZOLE- AND BENZOXAZOLE-4,7-DIONE DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131428-A1 BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS CDC25C, CDC25A, CDC25B HTT 4856/4885SMN1; SMN2 4855/4885ALDH1A1 1054/4885
US-20090137596-A1 G-PROTEIN INHIBITOR CDC25A, CDC25C, CDC25B HTT 4462/4885SMN1; SMN2 3763/4885ALDH1A1 2847/4885
US-20060281736-A1 Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent CDC25A, CDC25C, CDC25B HTT 4589/4885SMN1; SMN2 3760/4885ALDH1A1 2313/4885
US-20070293487-A1 BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS CDC25C, CDC25A, CDC25B HTT 4756/4885SMN1; SMN2 4854/4885ALDH1A1 868/4885
US-20070255063-A1 BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS CDC25A, CDC25C, CDC25B HTT 4571/4885SMN1; SMN2 4732/4885ALDH1A1 2061/4885
US-20060040996-A1 Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors DUSP5, DUSP15, CDC25C HTT 4788/4885SMN1; SMN2 4860/4885ALDH1A1 907/4885
US-20090253685-A1 Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent CDC25A, CDC25C, CDC25B HTT 4434/4885SMN1; SMN2 3708/4885ALDH1A1 2408/4885
US-20090082345-A1 BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS CDC25C, CDC25A, CDC25B HTT 4756/4885SMN1; SMN2 4854/4885ALDH1A1 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.